When it comes to the uncertainty that currently permeates the market as a result of the pandemic and impending election, the chief investment strategist at Oppenheimer is choosing to embrace it. As a result, today’s article takes a look at two specific stocks Oppenheimer is bullish on – and which its analysts believe have over 100% upside potential (792% in the case of one of the stocks!). For these two stocks – a clinical-stage biopharmaceutical company and a clinical-stage gene therapy company – CLICK HERE.
